9:00 am Chair’s Opening Remarks

Looking at Future Approvals & Current Pioneering Scientific Developments

9:20 am An Overview of the Successful Development of Loncastuximab tesirine, a PBD Based ADC Directed Against CD19 for the Treatment of Hematological Malignancies


• Review thepreclinical data for IND approval
• Gain an overview of manufacturing strategy
• Analyze the clinical data

9:40 am Small Molecule-drug Conjugates (SMDCs) & ADCs: A Comparative Evaluation

  • Dario Neri Professor of Biomacromolecules at the Department of Chemistry and Applied Biosciences, , ETH Zürich & Co-founder, Philogen


• Comparative biodistribution analysis of ADCs and SMDCs
• Comparative therapeutic performance of ADCs and SMDCs
• Exploring combination opportunities

10:00 am Live Discussion & Question Time

  • Dario Neri Professor of Biomacromolecules at the Department of Chemistry and Applied Biosciences, , ETH Zürich & Co-founder, Philogen
  • Patrick Van Berkel Senior Vice President - Resesarch & Development, ADC Therapeutics

10:30 am Morning Refreshments & Virtual Speed Networking


Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new
contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through
this exclusive virtual speed networking!

This session is a great opportunity to introduce yourself to the attendees that you would like to have more in-depth conversations
with. Get face-to-face time with many of the brightest minds working in the ADC field and establish meaningful business

1:00 pm Lunch & Networking

Looking at & Enhancing Novel Technologies & Hearing the Patients’ Story

2:20 pm Leveraging VelocImmuneTM Technologies to Advance Development of Next-Generation Antibody Conjugates

  • Bill Olson Senior Vice President, Therapeutic Proteins, Regeneron


• Regeneron’s VeclociSuiteTM technologies enable rapid generation of large panels of novel fully human antibodies, bispecific antibodies and humanized mouse models
• Reviewing these and other key technology platforms that provide powerful tools for generating and preclinically evaluating
innovative antibody conjugates spanning diverse disease areas and therapeutic mechanisms of action
• Outlining select examples that include conventional and bispecific antibodies conjugated to cytotoxic and immune-modulating agents

2:40 pm A Novel Globo H-targeting Antibody-drug Conjugate: OBI-999


• OBI-999 exhibited as a homogeneous ADC with drug-to-antibody ratio (DAR) at 4 (>95%) and presented Globo H-dependent
internalization and trafficking to endosome and lysosome within 1 to 5 hours
• OBI-999 showed a bystander killing effect based on co-culturing high Globo H expressing cancer cells with low Globo H
expression cancer cells.
• OBI-999 and MMAE were gradually accumulated at the tumor site, reaching its maximum level at 168 hour post treatment
• OBI-999 exhibited a significant tumor growth inhibition at dose dependent manner with doses of 1, 3, and 10 mg/kg
• The highest non severely toxic dose (HNSTD) in cynomolgus monkeys is 10 mg/kg determined by a 3-week repeated dose
toxicology study

3:00 pm Live Discussion & Question Time

  • Bill Olson Senior Vice President, Therapeutic Proteins, Regeneron
  • Ming-Tan Lai Head of Research & Development , OBI Pharma

3:30 pm Afternoon Refreshments & Networking Scientific Poster Session

4:00 pm Tumor-Targeted Immune-Stimulating Antibody Conjugates (ISAC): A New Class of Immuno-oncology Therapeutics

  • Brian Safina Vice President - Chemistry, Bolt Biotherapeutics


• Introducing Bolt’s ISAC technology platform as the next evolution in immune-oncology and antibody drug conjugates
• Showcasing key features of ISAC technology and mechanism of action
• Demonstrating the promise of the ISAC platform and Bolt’s approach to develop this new class

4:20 pm A Kadcyla Patient’s Experience: Hope & Healing


• One in eight
• Fight for life
• Better than before

4:40 pm Live Discussion & Question Time

5:00 pm Chair’s Closing Remarks